Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

NCT03829501 is registered in ClinicalTrials.gov with Kymab Limited as lead sponsor.

NCT NCT03829501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03829501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Lead sponsor
Kymab Limited
Phase
Phase 1/2
Overall status
Terminated
Start date
January 28, 2019
Completion date
October 3, 2024
Enrollment
222 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, cervical cancer, esophageal cancer, gastric cancer, hepatocellular carcinoma, melanoma, metastatic cancer, non-small cell lung cancer, pancreatic cancer, renal cell carcinoma, squamous cell carcinoma of head and neck, triple negative breast cancer